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Summary
Background Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal 
subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. We 
did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage.
Methods We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South America. We 
randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratiﬁ ed by centre) 
patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were 
admitted to hospital within 4 days of haemorrhage, to receive intravenous magnesium sulphate, 64 mmol/day, or 
placebo. We excluded patients with renal failure or bodyweight lower than 50 kg. Patients, treating physicians, and 
investigators assessing outcomes and analysing data were masked to the allocation. The primary outcome was poor 
outcome—deﬁ ned as a score of 4–5 on the modiﬁ ed Rankin Scale—3 months after subarachnoid haemorrhage, or 
death. We analysed results by intention to treat. We also updated a previous meta-analysis of trials of magnesium 
treatment for aneurysmal subarachnoid haemorrhage. This study is registered with controlled-trials.com (ISRCTN 
68742385) and the EU Clinical Trials Register (EudraCT 2006-003523-36).
Findings 1204 patients were enrolled, one of whom had his treatment allocation lost. 606 patients were assigned to 
the magnesium group (two lost to follow-up), 597 to the placebo (one lost to follow-up). 158 patients (26·2%) had 
poor outcome in the magnesium group compared with 151 (25·3%) in the placebo group (risk ratio [RR] 1·03, 
95% CI 0·85–1·25). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that 
magnesium is not superior to placebo for reduction of poor outcome after aneurysmal subarachnoid haemorrhage 
(RR 0·96, 95% CI 0·84–1·10). 
Interpretation Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid 
haemorrhage, therefore routine administration of magnesium cannot be recommended.
Funding Netherlands Heart Foundation, UK Medical Research Council.
Introduction
Prognosis after aneurysmal subarachnoid haemorrhage 
is poor; case fatality after 1 month is 27–44% and—
although case fatality seems to have decreased over 
the past 10 years—20% of survivors cannot live 
independently.1,2
Delayed cerebral ischaemia occurs usually between 
4 to 10 days after aneurysmal subarachnoid haemor-
rhage, and is an important cause of poor outcome.3,4 
Because of the interval between the onset of 
haemorrhage and the onset of cerebral ischaemia, 
outcome might be improved with treatments to prevent 
ischaemia.3 Oral nimodipine helps prevent delayed 
cerebral ischaemia after aneur ysmal subarachnoid 
haemorrhage, but despite its use delayed cerebral 
ischaemia aﬀ ects about 25% of patients receiving 
nimodipine.3,5
Magnesium is neuroprotective and has a well-
documented clinical proﬁ le.6 It is beneﬁ cial for treat-
ment of eclampsia, which shares pathophysiological 
mechanisms with delayed cerebral ischaemia.7,8 Mech-
anisms of neuroprotection by magnesium include 
inhibition of excitatory glutamate release, and blockage 
of the NMDA-glutamate receptor and voltage-dependent 
calcium channels.6,9 In our random ised phase 2 trial, 
which included 283 patients in The Netherlands, delayed 
cerebral ischaemia occurred in 22 of 139 (16%) patients 
who received intravenous magnesium 64 mmol/day 
plus usual care with oral nimodipine compared with 35 
of 144 (24%) patients who received placebo plus 
nimodipine. 38 of 139 (27%) patients who received 
magnesium had poor outcome versus 51 of 144 (35%) in 
the placebo group (risk ratio [RR] 0·77, 95% CI 
0·54–1·09).10 A Cochrane review5 of treatment with 
calcium antagonists after aneurysmal subarachnoid 
haemorrhage included three trials (379 patients) of 
magnesium in addition to nimodipine, and conﬁ rmed 
that intravenous magnesium plus nimodipine is 
superior to placebo for the prevention of delayed cerebral 
ischaemia (RR 0·66, 95% CI 0·45–0·96) and poor 
outcome (0·75, 0·57–1·00).
In this study, we test the eﬀ ect of intravenous 
magnesium sulphate on outcome after aneurysmal 
subarachnoid haemorrhage.
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Methods
Study design and patients
We did this phase 3 randomised, placebo-controlled trial 
at six Dutch, one Scottish, and one Chilean centre. The 
trial protocol has been published.11
Patients were eligible for inclusion if they were 
admitted to the neurological or neurosurgical units 
of one of the participating hospitals within 4 days of 
haemorrhage. Investigators based the diagnosis of 
aneurysmal sub arachnoid haemorrhage on the presence 
of extravasated blood in the basal cisterns by brain CT, 
or—if CT was negative—by xanthochromia of cerebro-
spinal ﬂ uid. For patients with a normal CT scan and 
xanthochromia of cerebrospinal ﬂ uid, proof of an 
aneurysm was a pre requisite for inclusion. We included 
patients with a perimes encephalic pattern of haemor-
rhage on CT only if they had an aneurysm of the 
posterior circulation. Exclu sion criteria were age younger 
than 18 years, renal failure (deﬁ ned as serum creatinine 
concentration of more than 150 μmol/L), bodyweight 
less than 50 kg, or imminent death. The study complies 
with the Declaration of Hel sinki and good clinical 
practice guidelines. We obtained ethics committee 
approval from every centre. All patients provided written 
and oral informed consent.
Randomisation and masking
The randomisation code was produced by the University 
Medical Center Utrecht (The Netherlands) pharmacy. The 
pharmacy used computer-generated randomisation codes 
in blocks of four, and stratiﬁ ed by centre. The pharmacy 
produced identical, sequentially numbered, randomly 
assigned boxes of study medication, contain ing either 
magnesium sulphate or placebo. Local investi gators 
assigned the participant to the box with the lowest study 
number. The randomisation key was kept by the pharmacy 
of the University Medical Center Utrecht. Patients, 
treating physicians, and investigators assessing outcomes 
and analysing data were masked to the allocation.
Procedures
At admission to hospital, investigators recorded sex, 
age, and World Federation of Neurological Surgeons sub-
arachnoid haemorrhage grade12 for each patient. A score 
of 1–3 was deemed a good clinical condition, and a score 
of 4–5 was deemed a poor clinical condition.
Study medication consisted of vials containing 
64 mmol magnesium sulphate or placebo (saline), 
produced by the pharmacy of the University Medical 
Center Utrecht and distributed to the participating 
centres (except for the centre in Chile, which produced 
its own study medication). An intravenous magnesium 
dosing regimen of 64 mmol per day after aneurysmal 
subarachnoid haemorrhage is safe and maintains 
serum magnesium concentrations at between 1·0 and 
2·0 mmol/L.13 Furthermore, sympto matic hypermagne-
saemia does not occur in patients with normal renal 
function.14 Therefore, participants received a ﬁ xed daily 
dose of 64 mmol magnesium sulphate reconstituted in 
0·9% saline, or placebo, as soon as possible after 
providing consent. Investigators admin istered study 
medi cation continuously via intravenous infusion and 
continued for 20 days after haemorrhage onset, or until 
hospital discharge or death if it occurred sooner. 
Investigators checked renal function at least once every 
2 days to prevent symptomatic hyper magnesaemia. 
Monitoring of magnesium concentration was not man-
datory. We discouraged, but permitted, investigators to 
treat hypomagnesaemia at admission with intravenous 
magnesium sulphate. Investigators treated patients 
according to local protocols, which included oral 
nimodipine 360 mg/day, bed rest until aneurysm occlu-
sion, and early aneurysm occlusion, and aimed at 
achievement of normovolaemia.
The primary outcome was dependence15 (deﬁ ned as a 
modiﬁ ed Rankin Scale score of 4 or 5) or death, 3 months 
after haemorrhage. The research nurse and study 
coordinator collected outcome data centrally, and 
assessed the Rankin score by semi-structured telephone 
interview in the patient’s own language. The interview 
Figure 1: Trial proﬁ le 
1204 patients enrolled
597 assigned to receive
placebo
606 assigned to receive
magnesium
1 lost to
follow-up
2 lost to
follow-up
596 analysed604 analysed
1 randomisation
code lost
Magnesium 
group 
(n=606)
Placebo 
group 
(n=597)
Mean age (SD; years) 57 (13) 57 (12)
Female (%) 422 (70%) 416 (70%)
World Federation of Neurological Surgeons 
subarachnoid haemorrhage grade >4
144 (24%) 130 (22%)
Aneurysm treatment
Coiling 344 (57%) 324 (54%)
Clipping 197 (33%) 195 (33%)
None 65 (11%) 76 (13%)
Unknown 0 (0%) 2 (<1%)
Median time to received study medication 
from symptom onset (IQR; h)
33 (21–60) 41 (23–59)
Table: Baseline characteristics
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was translated into Dutch and Spanish with the standard 
procedure16,17 for forward–backward translation. Secon-
dary outcome measures were no symptoms (modi ﬁ ed 
Rankin Scale score of 0) 3 months after haemorrhage 
and the diﬀ erence between the distribution of all scores 
on the modiﬁ ed Rankin Scale.
Statistical analysis
In our pilot study, 35% of patients in the untreated 
group had a poor outcome compared with 27% in the 
intervention group (RR 0·77).10 On the basis of these data 
we estimated that 1082 patients would be needed to 
conﬁ rm this eﬀ ect with an α of 5% and 80% power. To 
allow for reliable detection of a slightly smaller eﬀ ect 
(risk ratio 0·78) we decided to enrol 1200 patients. A 
research nurse entered all baseline and outcome data in 
the study database. The study coordinator analysed the 
data. The data were checked and results discussed by the 
executive committee. The data monitoring com mittee 
did two interim analyses during the study, after 350 and 
750 patients had completed 3-month follow-up, with 
reference to a pre-deﬁ ned stopping rule, and recom-
mended continuation of the trial on both occa sions. We 
analysed the results according to inten tion to treat by 
comparing poor outcome at 3 months in each group with 
a risk ratio and 95% CI. We did planned sensitivity 
analyses by assigning patients lost to follow-up to either a 
good outcome or a poor outcome irrespective of treat-
ment group, and assigning patients with unknown 
random isation codes to either the magnesium group or 
the placebo group. Planned subgroup analyses were 
done according to age, sex, clinical condition at 
admission, method of treatment of aneurysm, and 
whether the centre treated hypo magnesaemia with 
intravenous magnesium sup plementation. We com pared 
the distributions of the modiﬁ ed Rankin Scale scores 
with the non-parametric Mann-Whitney U test. We 
updated our previous Cochrane meta-analysis5 with 
results of MASH 2 and eligible randomised trials that 
had been published since the start of MASH 2 and the 
last update of the Cochrane review.18–20 We used Cochrane 
Review Manager (version 5.1) software for the meta-
analysis and SPSS (version 15.0) for all other analyses.
This study is registered with controlled-trials.com 
(ISRCTN 68742385) and the EU Clinical Trials Register 
(EudraCT 2006-003523-36).
Role of the funding source
The sponsor had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corres ponding author had full access to all data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
We enrolled 1204 participants between April, 2004, and 
September, 2011. Of these, 1124 were enrolled in The 
Netherlands, 59 in Scotland, and 21 in Chile. The ran-
domisation code of one patient was missing because the 
medication packaging containing the study number was 
lost, leaving 606 participants allocated to the magnesium 
group and 597 to the placebo group (ﬁ gure 1). Age, sex, 
clinical condition at admission, or method of aneurysm 
treatment did not diﬀ er substantially between the two 
Magnesium group
Placebo group
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
46 222 124 54 42 25 91
46 210 142 47 44 22 85
mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5 Death
Figure 2: Distributions of mRS score in the magnesium and placebo groups
Data are number of patients with each mRS score. Tested with Mann-Whitney U test; p=0·95. mRS=modiﬁ ed 
Rankin Scale score.
Magnesium
group (n/N)
Placebo
group (n/N)
Risk ratio (95% CI)
 122/421
 36/183
 47/282
 111/322
 79/460
 79/144
 33/65
 78/342
 47/197
 47/170
 111/434
 116/415
  35/181
  44/277
  107/319
  82/465
  68/130
  35/76
  66/323
  49/195
  48/155
  103/441
1·04 (0·84–1·29)
1·02 (0·67–1·54)
1·05 (0·72–1·53)
1·03 (0·83–1·28)
0·97 (0·74–1·29)
1·05 (0·84–1·31)
1·10 (0·78–1·55)
1·12 (0·84–1·49)
0·95 (0·67–1·34)
0·89 (0·64–1·25)
1·10 (0·87–1·38)
Women
Men
Age ≤55 years
Age >55 years
WFNS subarachnoid haemorrhage grade <4
WFNS subarachnoid haemorrhage grade 4–5
No treatment
Coiling
Clipping
Centre treats hypomagnesaemia
Centre does not treat hypomagnesaemia
Favours magnesium Favours placebo
0·2 0·5 1·0 2·0 5·0
Figure 3: Subgroup analyses for primary outcome
WFNS score was unknown for one patient. Treatment type was unknown for two patients. RR=risk ratio. 
WFNS=World Federation of Neurological Surgeons.12
Magnesium
group (n/N)
Placebo
group (n/N)
Risk ratio (95% CI)
Before MASH 2
Veyna 2002
Van den Bergh 2005
Wong 2006
Muroi 2008
Akdemir 2009
Wong 2010
Total
Heterogeneity: χ2=4·55, degrees of freedom=5 (p=0·47), I2=0%
MASH2
Total
Heterogeneity: χ2=6·02, degrees of freedom=6 (p=0·42), I2=0%
Test for subgroup diﬀerences: χ2=1·30, degrees of freedom=1 (p=0·25), I2=23·2%
 7/20
 38/139
 10/30
 11/31
 12/40
 57/169
 135/429
 158/604
 293/1033
 8/16
 51/144
 14/30
 14/27
 9/43
 52/158
 148/418
 151/596 
 299/1014
0·70 (0·32–1·52)
0·77 (0·54–1·09)
0·71 (0·38–1·35)
0·68 (0·38–1·24)
1·43 (0·68–3·03)
1·02 (0·75–1·39)
0·88 (0·73–1·07)
1·03 (0·85–1·25)
0·96 (0·84–1·10)
Favours magnesium Favours placebo
0·2 0·5 1·0 2·0 5·0
Figure 4: Meta-analysis of eﬀ ect of magnesium therapy after subarachnoid haemorrhage on poor outcome
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groups at baseline (table). Outcome data were un available 
for one patient in the placebo group and two in the 
magnesium group (99·8% of patients completed follow-
up). One was homeless with no available address or phone 
number, the second had been included while on holiday 
in The Netherlands, and the third could not be reached.
Magnesium had no eﬀ ect on the primary outcome; 
158 (26·2%) of 604 patients in the magnesium group and 
151 (25·3%) of 596 in the placebo group had a poor 
outcome (RR 1·03, 95% CI 0·85–1·25). The proportion 
of patients with no symptoms did not diﬀ er between 
the magnesium (46 of 604 patients; 7·6%) and placebo 
(46 of 596; 7·7%) groups (RR 0·99, 95% CI 0·67–1·46). 
Furthermore, the distribution of modiﬁ ed Rankin Scale 
scores between the magnesium and the placebo groups 
was not signiﬁ cantly diﬀ erent (p=0·95; ﬁ gure 2).
Subgroup analyses for poor outcome showed much the 
same estimates of eﬀ ect for women and men, old and 
young patients, good or poor clinical condition at 
admission, diﬀ erent methods of aneurysm treatment, 
and between centres that give magnesium for hypo-
magnesaemia (ﬁ gure 3).
According to the protocol, investigators reported only 
unexpected serious adverse events. Study treatment was 
stopped for one patient because of asymptomatic hypo-
calcaemia, for two patients because of asymptomatic 
hypermagnesaemia, and for one patient because of 
suspected symptomatic hypermagnesaemia, all of which 
occurred in the mag nesium group. The latter patient also 
had renal insuﬃ  ciency but study treatment was not 
stopped for this reason. This patient violated the protocol, 
which stipulated stopping treatment when serum 
creatinine concentration was higher than 150 μmol/L.
We updated our previous meta-analysis.5 Without the 
inclusion of MASH 2 data, poor outcome did not diﬀ er 
between magnesium and placebo groups (RR 0·88, 
95% CI 0·73–1·07), which is consistent with the results 
from another meta-analysis.21 Our ﬁ nal meta-analysis of 
2047 patients, including the MASH 2 results, showed no 
diﬀ erence between groups (RR 0·96, 0·84–1·10; ﬁ gure 4).
Discussion
Results from MASH 2 alone, and in combination with 
the other trial data (panel), show that intravenous 
magnesium does not aﬀ ect outcome after aneurysmal 
subarachnoid haemorrhage. Subgroup analyses did not 
identify a subgroup of patients who might beneﬁ t from 
magnesium treatment.
Various explanations exist for magnesium not 
improving outcome after aneurysmal subarachnoid 
haemorrhage. First, the putative pathophysiological 
mechanisms leading to delayed cerebral ischaemia and 
poor outcome after aneurysmal subarachnoid haemor-
rhage, which are targeted by magnesium treatment,6,9 
might not be as important as other mechanisms that are 
not known to be aﬀ ected by magnesium (eg, immediate 
ischaemia at the time of haemorrhage22). Second, 
magnesium is not known to aﬀ ect other complications of 
aneurysmal subarachnoid haemorrhage that aﬀ ect 
outcome, including hydrocephalus, rebleeding, electro-
lyte disturbances, hyperglycaemia, and cardiac and 
pulmonary dysfunction.23 Third, intravenously admin-
istered magnesium does not seem to cross the blood–
brain barrier well. Doubling serum magnesium leads 
to only an 11–21% increase in magnesium concentration 
in cerebrospinal ﬂ uid.24 However, higher serum mag-
nesium concentrations might cause systemic compli-
cations. Higher concentrations of magnesium in the 
subarachnoid space can be achieved by intracisternal 
infusion instead of intravenous infusions. This route of 
administration leads to intracranial vasodilatation but 
requires invasive techniques with cisternal and lumbar 
drains, which have higher risks of complication.25 Finally, 
vasodilation of cerebral arteries by magnesium does not 
necessarily prevent delayed cerebral ischaemia and 
improve outcome, since vasoconstriction is not the only 
cause of delayed cerebral ischaemia.26
Our trial has several strengths. The trial included many 
patients, was masked, and more than 99% of patients 
were followed up for assessment of a clinically relevant 
Panel: Research in context
Systematic review
We updated our previous Cochrane review5 with articles 
indexed by Medline before Jan 31, 2012. We also searched the 
Cochrane Stroke Group Trials Register (up to April 2006) and 
Embase (up to March 2006) for randomised controlled trials 
comparing magnesium sulphate versus control in addition to 
nimodipine. We then searched the reference lists of identiﬁ ed 
articles and contacted stroke investigators for details of other 
published and unpublished studies. Two reviewers (SDMD 
and AA, WMvdB, or GJER) independently extracted the data 
and assessed trial quality based on masking, outcome, type of 
analysis, and loss to follow-up. We excluded studies without 
control groups and those that were open-label. We contacted 
investigators to obtain missing information. The results of 
our meta-analysis showed no diﬀ erence between groups.
Interpretation
Randomised trials have suggested that magnesium is 
beneﬁ cial, but this ﬁ nding was not reproduced in MASH 2.5 
Previous studies were much smaller than MASH 2, and were 
not adequately powered, so the results might have been due 
to chance and might have been subject to publication bias. 
A randomised controlled trial of magnesium for aneurysmal 
subarachnoid haemorrhage—published when our study was 
still ongoing—was also neutral, but did not have enough 
power to deﬁ nitely rule out an eﬀ ect.20 The MASH 2 trial is the 
ﬁ rst adequately powered randomised controlled trial that 
shows no beneﬁ cial eﬀ ect of magnesium on outcome after 
aneurysmal subarachnoid haemorrhage, which is conﬁ rmed 
by our meta-analysis (ﬁ gure 4).18–20
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outcome. The treatment that the participants received is 
probably representative of care for aneurysmal sub-
arachnoid haemorrhage in middle-income to high-
income countries. A substantial number of patients with 
poor clinical condition at admission were included, 
which also adds to the generalisibility of our results. We 
have shown that a telephone interview is a reliable way of 
measuring the modiﬁ ed Rankin score in patients with 
aneurysmal subarachnoid haemorrhage.27
A limitation of our study is that we collected key 
baseline and outcome data, but did not call patients back 
for study visits for detailed assessment of quality of life. 
Because our study was pragmatically designed to assess 
whether magnesium improved clinical outcome after 
aneurysmal subarachnoid haemorrhage, we chose poor 
outcome as our primary outcome measure. Delayed 
cerebral ischaemia is only a surrogate or explanatory 
outcome measure, and so we did not include delayed 
cerebral ischaemia as a secondary outcome. For the 
same reason, we did not include other baseline 
measurements such as amount of blood in CT scan or 
systemic illness, nor did we do close on-site monitoring.
Furthermore, we do not have complete information 
about adherence to study medication. We did not require 
magnesium concentration to be routinely checked, in 
view of the results of our dose-ﬁ nding and safety studies.13,14 
We cannot exclude the possibility of un masking of 
investigators by checking patients’ serum magnesium 
concentrations, although such unmasking will not have 
aﬀ ected the primary or secondary outcome data, which 
were collected centrally by masked person nel. An eﬀ ect of 
magnesium treatment on cognitive symptoms—which 
are common after aneurysmal sub arachnoid haemor-
rhage28—might have been missed by the modiﬁ ed Rankin 
Scale. We measured clinical outcome 3 months after 
haemorrhage, which is a usual period for outcome 
assessment in stroke studies, and although a beneﬁ t 
might be detected later, we consider it unlikely in view of 
the probable mechanism of action of magnesium in the 
acute period after aneurysmal subarachnoid haemorrhage.
Magnesium has been studied in patients with 
ischaemic stroke and intracerebral haemorrhage in the 
IMAGES trial,29 which included almost 2600 patients, but 
did not show a beneﬁ cial eﬀ ect on outcome. In the 
IMAGES trial, median time from symptom onset to 
treatment was 7 h (only 3% of patients were treated 
within 3 h), which might be too long after ischaemic 
damage for a neuroprotective eﬀ ect. In our study, median 
time to treatment was 33 h in the magnesium group, 
which is similar to the median time in MASH 1 (28 h).10 
In the same way, time to treatment with magnesium in 
MASH 2 might not have been short enough to ameliorate 
acute ischaemic injury and prevent delayed cerebral 
ischaemia because the initiation of the cascade leading to 
secondary injury might be irreversible.
The MASH 2 trial has implications for clinical prac-
tice. Administration of magnesium after aneurysmal 
subarachnoid haemorrhage is standard practice in many 
centres. On the basis of the results of MASH 2—a trial of 
treatment of aneurysmal subarachnoid haemorrhage 
with suﬃ  cient power to detect a clinically signiﬁ cant 
improvement in outcome—and in com bination with 
data from other trials, we do not recommend routine 
use of intravenous magnesium 64 mmol/day for the 
improvement of outcome after aneurysmal subarachnoid 
haemorrhage.
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